- Stocks Could Get a Short Post-Election Bounce
- Burger King Sales Strong, Despite Downturn
- EA Shares Skid After Videogame Maker Slashes Forecast
- Stock Picks: Tech, Retail, Beer & More
- Treasurys Flat as Economic Gloom Prevails
- Commodities Prices Get Pummeled During October
- Banks Must Use Bailout Funds for Lending: Rep. Frank
- Coming Soon: Congress Is Back With 'Stimulus-2'
- Clorox Quarterly Earnings Top Expectations
- Lightning Round: Merck, Deere, Altria and More
- Your First Move For Monday November 3rd
- Lightning Round OT: Morgan Stanley, Solarfun Power and More
- Buy Boardwalk Pipeline
- Is It Splitsville for Marathon Oil?
- Week Ahead Web Extra
- Game Plan: Why the U.S. Still Needs Help
- Pops & Drops: General Motors, Citigroup...
- Now Onto November
- Hong Kong's Cathay Pacific to sell 5 planes
- Study: Media coverage favors Obama
- Sun-Times shareholder demands ouster of CEO
- Stocks end Oct. with worst performance in 21 years
- Contract talks extended with Cooper Tire and union
- Movers roundup: Cigna, Electronic Arts
- Molex Inc. buys 2 million shares from co-chairman
- American National Insurance sets 77-cent dividend
- Fitch cuts Hartford Financial Services IDR ratings
- Tredegar sets 4-cent quarterly dividend
Moody's considers downgrading PharmaNet
NEW YORK - Moody's Investors Service said Friday it will consider downgrading its debt rating on PharmaNet Development Group Inc., a drug development services company.
Moody's cited a high rate of contract cancellations and doubts about the Princeton, N.J.-based company's ability to favorably refinance $144 million in convertible notes.
Holders will be able to exercise options on the notes in August.
Moody's currently has a "B3," or non-investment "junk," rating on PharmaNet. About $45 million of rated debt is affected.
The company's stock rose 54 cents, or 37 percent, to $2 in afternoon trading.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tools:

